Vaccine

DGAP-News: CureVac Chief Technology Officer to Pursue New Career outside Biotech Industry

Retrieved on: 
Monday, January 17, 2022 - 12:04pm
Technology, RNA, COVID-19, Degenerative disease, CureVac, Protein, Leadership, Nasdaq, Infection, GSK, Supervisory board, Therapy, Mariola, Personality, Cell biology, CVAC, RNA transfection, Senior, Management, Vaccine

Further development of CureVac's unique mRNA technology platform will be led by Dr. Igor Splawski, Chief Scientific Officer of CureVac, and spearheaded by Dr. Patrick Baumhof, Senior Vice President Technology, who has a 15-year scientific tenure with the company.

Key Points: 
  • Further development of CureVac's unique mRNA technology platform will be led by Dr. Igor Splawski, Chief Scientific Officer of CureVac, and spearheaded by Dr. Patrick Baumhof, Senior Vice President Technology, who has a 15-year scientific tenure with the company.
  • "Mariola's dedication and expertise helped to build CureVac and fundamentally contributed to the advancement of mRNA technology as a whole."
  • "Mariola's groundbreaking work and innovations in mRNA technology have strongly contributed to CureVac becoming the world's pioneering company to harness mRNA for medical purposes," added Dr. Franz-Werner Haas, Chief Executive Officer of CureVac.
  • Mariola Fotin-Mleczek joined CureVac in May 2006 and became a member of the management board in 2013, first as Chief Scientific Officer and as Chief Technology Officer in 2018.

Evelo Biosciences Presents Data on EDP1815 Mechanism of Action and Supporting Ongoing Clinical Development for Inflammatory Diseases

Retrieved on: 
Monday, January 17, 2022 - 12:00pm
Atopic dermatitis, Patient, Research, TLR2, Inflammation, Confidentiality, Clinical trial, Private Securities Litigation Reform Act, SEC, COVID-19, Oral medicine, Effectiveness, Growth, Risk, GLOBE, Ownership, Psoriasis, Immunosuppression, Marketing, Preclinical development, Pharmacology, Immune system, Failure, Pharmaceutical industry, Vaccine, T helper cell, Dermatology

The data were presented in two posters on Saturday, January 15, 2022, at the 2022 Winter Clinical Dermatology Congress in Koloa, Hawaii.

Key Points: 
  • The data were presented in two posters on Saturday, January 15, 2022, at the 2022 Winter Clinical Dermatology Congress in Koloa, Hawaii.
  • The data presented today build on the substantial evidence accumulated through our clinical and preclinical work, deepening our understanding of the mechanism by which EDP1815 drives its clinical effects.
  • B.Chir, Dermatology and Pharmacology Physician at Addenbrookes Hospital and Immunology Clinical Lead of Evelo.
  • Evelo currently has three product candidates in development: EDP1815, EDP1867, and EDP2939 for the treatment of inflammatory diseases.

Stallergenes Greer Strengthens Precision Medicine Approach in Allergen Immunotherapy With Imperial College London Research Collaboration

Retrieved on: 
Monday, January 17, 2022 - 11:37am
Science, Research, Pharmaceutical, Health, Infectious Diseases, University, Education, Clinical Trials, Biomarker, Medicine, Patient, Research, Virology, AIT, Publication, International, Reuters, Precision medicine, COVID-19, Science, Knowledge, Immunomodulation, HIV disease progression rates, Rankings of universities in the United Kingdom, Disease, Student, NHS, Review, Industry, Allergy, Times Higher Education, Time, Diagnosis, Imperial, Immune system, College, Engineering, Stallergenes Greer, Imperial College London, Partnership, University, Pharmaceutical industry, Vaccine

Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), today announced that the company has entered into a research collaboration on the discovery of biomarkers of AIT efficacy with Imperial College London, a global top ten university with a world-class reputation in science, engineering, business and medicine.

Key Points: 
  • Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), today announced that the company has entered into a research collaboration on the discovery of biomarkers of AIT efficacy with Imperial College London, a global top ten university with a world-class reputation in science, engineering, business and medicine.
  • This underscores our commitment to advancing precision medicine for allergy sufferers, stated Amer Jaber, Executive VP Operations Europe and International and President of Stallergenes SAS.
  • This research collaboration is a remarkable opportunity for a fruitful partnership between Imperial College London, a pioneer and world-leading university in the biomarker field, and Stallergenes Greer.
  • It will build on the recent advances of biomarker research to further develop precision medicine in AIT for the benefit of patients with allergic diseases, said Dr Mohamed Shamji, Head of the Immunomodulation and Tolerance Group, Imperial College London.

Global Chemiluminescence Immunoassay Market Report 2021-2028 - Focus on Consumables, Instruments, Software & Services - ResearchAndMarkets.com

Retrieved on: 
Monday, January 17, 2022 - 11:18am
Biotechnology, Health, Oncology, CAGR, Application, DiaSorin, American Cancer Society, Severe acute respiratory syndrome coronavirus 2, Adoption, CLIA, Disease, Solution, Software, HIV, Consumables, WHO, Qiagen, Cancer, Prevalence, Hospital, Conditional sentence, Endocrinology, Awareness, Medical device, Vaccine, Video game

The "Global Chemiluminescence Immunoassay Market Size, Share & Trends Analysis Report by Product (Consumables, Instruments, Software & Services), by Application, by End-use, by Region, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Chemiluminescence Immunoassay Market Size, Share & Trends Analysis Report by Product (Consumables, Instruments, Software & Services), by Application, by End-use, by Region, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.
  • Key players in the market are implementing organic and inorganic growth strategies for the development, launch, and distribution of novel CLIA solutions.
  • However, the high setup cost of automated chemiluminescence immunoassay systems is expected to be a major factor hindering the market growth.
  • The emergence of local players in developing markets, such as India and China, is primarily driving the regional market

Antech introduces veterinary medicine's most advanced parasite screening test

Retrieved on: 
Monday, January 17, 2022 - 11:30am
Immunodeficiency, Hookworm, Human, MDR, Coccidia, LinkedIn, Degenerative disease, Refrigeration, Dog, Veterinarian, R, VMX, Precision medicine, Molecular diagnostics, COVID-19, Toxoplasma gondii, Disease, DNA, Leadership, Health, PETS, FVH, Time, View, Cestoda, One Health, Education, Efficiency, Cat, Parasitic disease, Color, Multimedia, Veterinary medicine, Risk, Zoonosis, Twitter, Family, Prevalence, Companion Animal Parasite Council, Awareness, Medical imaging, Vaccine, Beef cattle, Medical device, Parasitism, Instagram, Facebook, Expo

Antech's investment in molecular technology, including 10 testing locations across North America, supports affordable next-day results, making advanced molecular parasite screening practical for routine wellness exams.

Key Points: 
  • Antech's investment in molecular technology, including 10 testing locations across North America, supports affordable next-day results, making advanced molecular parasite screening practical for routine wellness exams.
  • However, today's parasitic infection challenges have outpaced the capabilities of existing screening tests, the most common being the 100-year-old Ova and Parasite (O&P) diagnostic protocol.
  • KeyScreen GI Parasite PCRoffers several novel capabilities, supporting practice efficiency, rapid, cost-effective detection of more disease and a new, higher standard of care for parasite screening.
  • Today, Antech is driving the future of pet health as part of Mars Veterinary Health, a family-owned enterprise focused on veterinary care.

Global Immunoassay Markets 2021-2028 - Introduction of PoC Rapid Tests and Automated Immunoassay Analyzers is Driving Market Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, January 17, 2022 - 10:48am
Health, Other Health, Well, National Cancer Institute, CAGR, Myocardial infarction, Application, Antigen, EIA, Incidence, Enzyme immunoassay, POC, Antibody, SRL Diagnostics, COVID-19, Malaria, American Cancer Society, Death, RIA, Software, Infection, HIV, WHO, Reagent, USD, Cancer, Smartphone, ELISA, Awareness, Medical device, Vaccine, Dietary supplement, Technology

The global immunoassay market size is expected to reach USD 36.7 billion by 2028 and is expected to expand at a CAGR of 6.7% from 2021 to 2028.

Key Points: 
  • The global immunoassay market size is expected to reach USD 36.7 billion by 2028 and is expected to expand at a CAGR of 6.7% from 2021 to 2028.
  • The introduction of PoC rapid tests and automated immunoassay analyzers is driving the market growth.
  • In addition, the rising number of chronic and infectious diseases is also leading to high market growth.
  • Several smartphone-based devices and associated tools have emerged as next-generation point-of-care diagnostics or testing devices, boosting the market growth.

Brazil’s SENAI CIMATEC Doses First Healthy Volunteers in Phase 1 trial of HDT Bio’s RNA COVID-19 Vaccine

Retrieved on: 
Monday, January 17, 2022 - 10:30am
Research, Infectious Diseases, FDA, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, All-China Federation of Industry and Commerce, Vaccination, Research, Technology, Ministry, Safety, Vaccine, Clinical trial, Incidence, Biotechnology, RNA, COVID-19, Population, Adult, Volunteering, Phase II, Health, Infection, Industry, Education, HDT, Doctor of Philosophy, Therapy, Immune system, Engineering, Principal, SENAI, Partnership, Trial of the century, Science

SENAI CIMATEC will conduct the clinical trial under the name Vaccine RNA MCTI-CIMATEC-HDT.

Key Points: 
  • SENAI CIMATEC will conduct the clinical trial under the name Vaccine RNA MCTI-CIMATEC-HDT.
  • The first was in India with our partner Gennova Biopharmaceuticals which has moved the vaccine into Phase 2 and Phase 3 trials.
  • HDT Bio has other partnerships for its RNA COVID-19 vaccine, including in South Korea and China.
  • HDT Bios innovative vaccine, which also will undergo a Phase 1 trial in the U.S. , uses its proprietary lipid nanoparticle carrier system for delivery of RNA.

Neurimmune expands drug discovery collaboration with Ono Pharmaceutical in the field of neurodegenerative diseases

Retrieved on: 
Monday, January 17, 2022 - 10:04am
Neurodegeneration, Research, Patient, Frontotemporal dementia, ATTR, CSO, Discovery, Antibody, CNS, Parkinson's disease, Partnership, Ono, RTM, ALS, Therapy, Lewy body, Ono Pharmaceutical, Senior, Alzheimer's disease, Dementia, Amyotrophic lateral sclerosis, Pharmaceutical industry, Vaccine, Biogen

ZURICH, Jan. 17, 2022 Neurimmune AG today announced that it has signed an expanded drug discovery collaboration agreement with Ono Pharmaceutical Co., Ltd.

Key Points: 
  • ZURICH, Jan. 17, 2022 Neurimmune AG today announced that it has signed an expanded drug discovery collaboration agreement with Ono Pharmaceutical Co., Ltd.
  • In November 2017, Ono and Neurimmune signed a first drug discovery collaboration agreement to identify and develop human antibodies using the RTMtechnology platform.
  • In the new collaboration, the companies aim to generate and validate human-derived monoclonal antibodies against Ono's newly selected drug targets.
  • "The joint goal of the collaboration is to discover novel drug candidates for the treatment of neurodegenerative diseases using RTM technology."

Ascletis Announces U.S. IND Approval of ASC22 (Envafolimab), a Subcutaneously Administered PD-L1 Antibody for Functional Cure of Chronic Hepatitis B

Retrieved on: 
Monday, January 17, 2022 - 10:08am
Research, Gannex, Liver cancer, HKEX, Cornerstone, Acne, CHB, Investigational New Drug, Prevalence, PD-1, RNA, COVID-19, GBM, Safety, Hong Kong Stock Exchange, NASH, Hepatitis B, Nas, CDC classification system for HIV infection, Hepatitis C, WHO, OBI Pharma, Inc., FXR, Doctor of Philosophy, HBsAg, Food, World Health Organization, Phase, Interim, FDA, Patient, Institute of Liver and Biliary Sciences, World, Association, HBV, IIB, DHHS, American Association, Pegasys, R, American Association for Cancer Research, AASLD, RNA polymerase II, CEO, Degenerative disease, IND, Hepatitis B virus, HIV/AIDS, FASN, PBC, Food and Drug Administration, PD-L1, THR, United States Department of Health and Human Services, Vaccine, Pharmaceutical industry, Medical device, Cancer

HANGZHOU and SHAOXING, China, Jan. 17, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) announces today the Investigational New Drug (IND) application approval by U.S. Food and Drug Administration (FDA) and initiation of global development of ASC22 (Envafolimab), a first-in-class, subcutaneously administered PD-L1 antibody for functional cure of chronic hepatitis B (CHB).

Key Points: 
  • Such inclusion is a singular honor and indicates the high level with which the AASLD review committee regards Ascletis' research in CHB functional cure.
  • "ASC22 (Envafolimab) U.S. IND approval enables us to initiate U.S. and global clinical trials for CHB functional cure.
  • Viral Diseases: (1) Hepatitis B Virus (functional cure): focus on breakthrough therapies for CHB functional cure with a subcutaneously-injected PD-L1 antibody ASC22 and Pegasys as cornerstone drugs.
  • (3) HIV/AIDS: ASC22, an immune therapy to restore HIV-specific immune responses and eventually lead to a functional cure of HIV-infected patients.

Insights on the Oral Rehydration Salts Global Market to 2027 - Featuring Cian Healthcare, Doyen Healthcare and Merck Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, January 17, 2022 - 9:49am
Medical Supplies, Health, Use, Region, CAGR, Profile, Customer support, Market share analysis, R, COVID-19, Value, Growth, Acquisition, Distribution, Strategic management, Form, USD, Certification, Decision-making, Business Growth Fund, Investment, Retail, Fine chemical, Vaccine

What are the inhibiting factors and impact of COVID-19 shaping the Global Oral Rehydration Salts Market during the forecast period?

Key Points: 
  • What are the inhibiting factors and impact of COVID-19 shaping the Global Oral Rehydration Salts Market during the forecast period?
  • Which are the products/segments/applications/areas to invest in over the forecast period in the Global Oral Rehydration Salts Market?
  • What is the market share of the leading vendors in the Global Oral Rehydration Salts Market?
  • What modes and strategic moves are considered suitable for entering the Global Oral Rehydration Salts Market?